– Award to provide US$2 million to support Zucara’s planned Phase 2a ZONE trial, with first patient dosing expected in Q3 2023 – Toronto, Canada, June 15, 2023 – Zucara Therapeutics Inc., (“Zucara” or the “Company”) a diabetes-focused life sciences company developing the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people […]